Lin, Nancy U. http://orcid.org/0000-0003-2263-5413
Kumthekar, Priya
Sahebjam, Solmaz http://orcid.org/0000-0001-9930-9937
Ibrahim, Nuhad http://orcid.org/0000-0001-8660-243X
Fung, Anita
Cheng, Anna
Nicholas, Alan
Sussell, Jesse
Pegram, Mark http://orcid.org/0000-0002-9743-8118
Funding for this research was provided by:
Roche
Genentech
Article History
Received: 3 February 2023
Accepted: 27 September 2023
First Online: 17 November 2023
Competing interests
: N.U.L.—institutional research support: Genentech, Inc., Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca; consulting honoraria: Puma, Seattle Genetics, Daichii-Sankyo, AstraZeneca, Denali Therapeutics, Prelude Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, Blueprint Medicines; stock and other ownership interests: Artera Inc. (<$50k and <5% as it relates to consulting activities – options are not currently valued or in-hand); royalties (book). P.K.—advisory board fees: Enclear Therapies, Affinia Therapeutics, Biocept, Janssen, Sintetica, Bioclinica, Novocure, Mirati Therapeutics, Inc., Orbus Therapeutics; contracted research: Genentech, Inc., Novocure, DNAtrix, Orbus Therapeutics; scientific consultant: Enclear Therapies (with grant options provided); patent holder: European Patent 3307327, August 12, 2020, US Patent Pending 15/737,188 (no financial gain). S.S.—research funding: Merck, Bristol Myers Squibb, Brooklyn ImmunoTherapeutics; advisory consultation: Merck and Boehringer Ingelheim (all unrelated to this manuscript). N.I.—none. A.F., A.C., A.N., and J.S.—employment: Genentech, Inc.; shareholder: F. Hoffmann-La Roche Ltd. M.P.—consulting role(s): F. Hoffmann-La Roche Ltd./Genentech, Inc., SeaGen/Pfizer, AstraZeneca/Daiichi Sankyo.